傲农生物
(603363)
| 流通市值：81.82亿 | | | 总市值：133.27亿 |
| 流通股本：15.98亿 | | | 总股本：26.03亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,335,161,290.25 | 3,956,933,251.63 | 1,783,121,593.7 | 8,762,672,770.35 |
| 营业收入 | 6,335,161,290.25 | 3,956,933,251.63 | 1,783,121,593.7 | 8,762,672,770.35 |
| 二、营业总成本 | 6,392,792,809.51 | 3,978,013,252.97 | 1,810,542,498.52 | 10,238,602,637.79 |
| 营业成本 | 5,862,439,724.36 | 3,628,193,633.66 | 1,631,555,968.48 | 8,366,781,012.18 |
| 税金及附加 | 19,554,616.43 | 12,813,952.07 | 7,275,556.84 | 29,633,858.93 |
| 销售费用 | 150,584,107.21 | 95,086,651.28 | 42,113,106.03 | 263,557,957.37 |
| 管理费用 | 227,195,286.67 | 154,120,576.71 | 84,028,013.77 | 870,097,937.53 |
| 研发费用 | 34,392,991.93 | 21,803,331.46 | 9,845,699.8 | 54,469,739.41 |
| 财务费用 | 98,626,082.91 | 65,995,107.79 | 35,724,153.6 | 654,062,132.37 |
| 其中:利息费用 | 100,113,642.26 | 67,089,286.6 | 36,492,427.86 | 650,953,240.6 |
| 其中:利息收入 | 2,652,348.69 | 1,743,889.16 | 1,161,276.74 | 1,597,435.61 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -3,070 | 37,140 | -7,880 | -26,859,346.21 |
| 加:投资收益 | 441,756,019.59 | 372,837,359.85 | 250,414,865.92 | 2,041,414,592.45 |
| 资产处置收益 | 9,726,905.9 | 270,002.62 | -192,728.04 | 46,159,637.47 |
| 资产减值损失(新) | - | - | - | -137,651,322.86 |
| 信用减值损失(新) | -25,573,940.36 | -18,373,915.03 | -6,892,851.2 | -104,845,097.76 |
| 其他收益 | 31,928,864.99 | 19,886,713.85 | 10,924,779.48 | 75,134,463.96 |
| 四、营业利润 | 400,203,260.86 | 353,577,299.95 | 226,825,281.34 | 417,423,059.61 |
| 加:营业外收入 | 22,197,697.94 | 12,217,781.4 | 5,528,472.25 | 31,286,451.98 |
| 减:营业外支出 | 10,494,107.49 | 4,535,673.21 | 6,966,221.66 | 364,214,631.49 |
| 五、利润总额 | 411,906,851.31 | 361,259,408.14 | 225,387,531.93 | 84,494,880.1 |
| 减:所得税费用 | -27,263,782.15 | -14,134,224.96 | 3,716,508.08 | 21,403,298.76 |
| 六、净利润 | 439,170,633.46 | 375,393,633.1 | 221,671,023.85 | 63,091,581.34 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 439,170,633.46 | 375,393,633.1 | 221,671,023.85 | 63,091,581.34 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 413,933,328.13 | 360,801,140.43 | 218,305,329.33 | 579,345,018.87 |
| 少数股东损益 | 25,237,305.33 | 14,592,492.67 | 3,365,694.52 | -516,253,437.53 |
| 扣除非经常损益后的净利润 | -61,026,405.63 | -29,743,035.83 | -35,064,636.73 | -1,202,508,098.93 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.14 | 0.08 | 0.67 |
| (二)稀释每股收益 | 0.16 | 0.14 | 0.08 | 0.67 |
| 八、其他综合收益 | -623,386.56 | -429,036.05 | -214,145.44 | -13,310,722.46 |
| 归属于母公司股东的其他综合收益 | -623,386.56 | -429,036.05 | -214,145.44 | -13,310,722.46 |
| 九、综合收益总额 | 438,547,246.9 | 374,964,597.05 | 221,456,878.41 | 49,780,858.88 |
| 归属于母公司股东的综合收益总额 | 413,309,941.57 | 360,372,104.38 | 218,091,183.89 | 566,034,296.41 |
| 归属于少数股东的综合收益总额 | 25,237,305.33 | 14,592,492.67 | 3,365,694.52 | -516,253,437.53 |
| 公告日期 | 2025-10-28 | 2025-08-26 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |